Qdenga, cleared this week for ages 4 to 60, is one of only a few dengue vaccines in the world. It is to be injected in two doses three months apart.

Dengue vaccine Qdenga is likely to be arrive in India early next year. Is this a new vaccine? Can it stop outbreaks? Who can ...

India approved its first dengue vaccine, Takeda's QDENGA, for ages 4–60. The two-dose vaccine protects against all four strains, cuts severe disease and hospitalisation, and complements mosquito ...

India has approved its first dengue vaccine, QDENGA, in a step against a disease that has become an increasingly large public health challenge in the country. The approval comes as dengue cases in the ...

India has approved its first dengue vaccine, QDENGA, for people aged 4 to 60 years. Know who can receive it, how the two-dose vaccine works, why it does not require pre-vaccination screening and what ...

The two-dose vaccine protects against all four dengue virus strains without requiring pre-vaccination testing, as India battles a rising dengue burden.

India approves Takeda's QDENGA dengue vaccine for ages 4-60, offering protection against all virus serotypes without prior screening.

While the indigenous malaria vaccine, AdFalciVax, is under evaluation, a dengue vaccine is currently in Phase 3 trials with ...

A study suggests the hexavalent vaccine could enhance India's immunisation efficiency by reducing injections and easing ...

Takeda's QDENGA has been approved for people aged 4–60, offering a new prevention tool as dengue cases and the wider disease burden remain a public health challenge.

Takeda Pharmaceutical's dengue vaccine Qdenga has been approved by India's drug regulator, making it the first such vaccine to be cleared in the country, the Japanese drugmaker's ​India unit said on ...

A study appearing in Human Vaccines & Immunotherapeutics found that introducing the hexavalent (six-in-one) vaccine into India's Universal Immunization Program (UIP) could improve the efficiency of ...